2,346
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Uncovering the regional localization of inhaled salmeterol retention in the lung

, , , , , , & show all
Pages 838-845 | Received 02 Feb 2018, Accepted 19 Mar 2018, Published online: 28 Mar 2018

References

  • Bäckman P, Arora S, Couet W, et al. (2018). Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. Eur J Pharm Sci 113:41–52.
  • Bäckström E, Boger E, Lundqvist A, et al. (2016a). Lung retention by lysosomal trapping of inhaled drugs can be predicted in vitro with lung slices. J Pharm Sci 105:3432–9.
  • Bäckström E, Lundqvist A, Boger E, et al. (2016b). Development of a novel lung slice methodology for profiling of inhaled compounds. J Pharm Sci 105:838–45.
  • Berry KA, Li B, Reynolds SD, et al. (2011). MALDI imaging MS of phospholipids in the mouse lung. J Lipid Res 52:1551–60.
  • Boger E, Ewing P, Eriksson UG, et al. (2015). A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships. J Pharmacol Exp Ther 353:279–87.
  • Borghardt JM, Weber B, Staab A, et al. (2016). Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br J Clin Pharmacol 81:538–52.
  • Caldwell RL, Caprioli RM. (2005). Tissue profiling by mass spectrometry: a review of methodology and applications. Mol Cell Proteomics 4:394–401.
  • Caprioli RM, Farmer TB, Gile J. (1997). Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69:4751–60.
  • Cazzola M, Testi R, Matera MG. (2002). Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 41:19–30.
  • Cooper AE, Ferguson D, Grime K. (2012). Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab 13:457–73.
  • Dolovich M, Labiris R. (2004). Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc 1:329–37.
  • Gerde P, Scott BR. (2001). A model for absorption of low-volatile toxicants by the airway mucosa. Inhal Toxicol 13:903–29.
  • Hankin JA, Barkley RM, Murphy RC. (2007). Sublimation as a method of matrix application for mass spectrometric imaging. J Am Soc Mass Spectrom 18:1646–52.
  • Hendrickx R, Lamm Bergstrom E, Janzen DLI, et al. (2017). Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators. CPT Pharmacometrics Syst Pharmacol. [Epub ahead of print]. doi: 10.1002/psp4.12270
  • Labiris NR, Dolovich MB. (2003a). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–99.
  • Labiris NR, Dolovich MB. (2003b). Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:600–12.
  • Leach C, Colice GL, Luskin A. (2009). Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 124:S88–S93.
  • Marko-Varga G, Fehniger TE, Rezeli M, et al. (2011). Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J Proteomics 74:982–92.
  • Matsumoto T, Kushida H, Matsushita S, et al. (2017). Distribution analysis via mass spectrometry imaging of ephedrine in the lungs of rats orally administered the Japanese kampo medicine maoto. Sci Rep 7:44098.
  • Nilsson A, Fehniger TE, Gustavsson L, et al. (2010). Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS One 5:e11411.
  • Pavord ID, Beasley R, Agusti A, et al. (2018). After asthma: redefining airways diseases. Lancet 391:350–400.
  • Prideaux B, Dartois V, Staab D, et al. (2011). High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83:2112–18.
  • Stein SW, Thiel CG. (2017). The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv 30:20–41.
  • Sun N, Fernandez IE, Wei M, et al. (2016). Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. Histochem Cell Biol 145:201–11.
  • Swales JG, Tucker JW, Strittmatter N, et al. (2014). Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis. Anal Chem 86:8473–80.
  • Sykes DA, Parry C, Reilly J, et al. (2014). Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing “micro-pharmacokinetic/pharmacodynamic relationships” at the beta2-adrenoceptor. Mol Pharmacol 85:608–17.
  • Zecchi R, Trevisani M, Pittelli M, et al. (2013). Impact of drug administration route on drug delivery and distribution into the lung: an imaging mass spectrometry approach. Eur J Mass Spectrom (Chichester) 19:475–82.
  • Zemski Berry KA, Murphy RC, Kosmider B, et al. (2017). Lipidomic characterization and localization of phospholipids in the human lung. J Lipid Res 58:926–33.